DA-302168S is a GLP-1R agonist. DA-302168S exhibits higher potency both in vitro/in vivo while mitigating the risk of drug−drug interaction compared to other reported candidate compounds. Preclinical studies show full efficacy in cAMP activation, glucose reduction, and appetite suppression. Safety assessments reveal minimal risks with hERG IC50 > 30 μM and no significant offtarget toxicity. Its favorable pharmacokinetics support once-daily oral dosing, improving patient compliance.
MedKoo Cat#: 128775
Name: DA-302168S
CAS#: N/A
Chemical Formula: C33H24ClF2N3O5
Exact Mass: 615.1373
Molecular Weight: 616.02
Elemental Analysis: C, 64.34; H, 3.93; Cl, 5.75; F, 6.17; N, 6.82; O, 12.99
The following data is based on the product molecular weight 616.02 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
